Oncology-focused biopharma developing differentiated cancer therapies including samuraciclib.
| Date | Round | Amount |
|---|---|---|
| Dec 2022 | Series C Irish oncology biopharma Carrick Therapeutics raised $25m in Series C from existing investors to fund clinical trials of its cancer therapies. | $25M |
| Dec 2022 | Funding round Pfizer made a separate $35m strategic investment in Carrick Therapeutics to develop samuraciclib for advanced breast cancer. | $35M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.